Telix to Acquire ITM in $1.65B Radiopharmaceutical Merger

What happened. Australia’s Telix Pharmaceuticals (ASX:TLX, also Nasdaq-listed) agreed to acquire Germany’s ITM Isotope Technologies Munich SE for about $1.65 billion upfront on a cash-free, debt-free basis, in a deal announced Monday, September 21, 2026. The consideration is roughly $1.25 billion in Telix shares at $11.84 per share, about $302 million of ITM net debt assumed, plus a $96 million management equity rollover. Up to $700 million more in contingent payments tied to regulatory approvals and sales milestones for ITM-11 bring the total potential value to $2.35 billion. Telix shareholders would own about 76.3% of the combined company, with ITM holders at roughly 23.7%.

The combined company is expected to generate pro forma 2026 revenue and income above $1.3 billion, a management estimate. ITM’s radioisotope manufacturing business produced $273 million in 2025 revenue — a 40% compound annual growth rate since 2021 — and is profitable, with combined operating earnings expected to turn positive from 2027. ITM is the sole producer of globally scaled commercial-grade lutetium-177, with production and distribution spanning more than 65 countries. Closing is expected by year-end 2026, subject to shareholder and regulatory approvals; 90% of ITM stakeholders backed the deal at signing. One wrinkle: the FDA rejected ITM-11’s (177Lu-edotreotide) application last month over manufacturing issues — no safety or efficacy concerns were cited — and ITM plans to resubmit; a resubmission or an agreed path forward is a closing condition. Telix shares slipped nearly 6% to A$16.82 on the news.

Why it matters. This is a landmark consolidation in radiopharmaceuticals, one of healthcare’s fastest-growing niches. Telix isn’t just buying revenue — it is buying the isotope supply chain itself. Lutetium-177 is the backbone of targeted cancer radiotherapy, and owning the only globally scaled commercial source gives the combined company pricing power and a moat that drug pipelines alone cannot provide. The nearly 6% drop in Telix shares suggests investors are weighing dilution and integration risk against that strategic prize. For the broader biotech sector, the deal’s contingent structure — $700 million tied to ITM-11 milestones — shows how buyers are sharing regulatory risk in the wake of last month’s FDA rejection. Related reading: more biotech coverage in our Market News forum.

What to watch. The shareholder and regulatory approvals needed for a year-end close, ITM’s FDA resubmission path for ITM-11 (a closing condition), and whether the combined company delivers the promised positive operating earnings from 2027.

Discussion question: Is owning the lutetium-177 supply chain worth up to $2.35 billion, or is Telix overpaying for a manufacturing moat?

Sources:
SRN News (Reuters)
Radiology Business

Auto-posted by the Bull Lounge news desk.
Not financial advice.